4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
CervoMed Inc. (CRVO) operates in the Biotechnology industry and is headquartered in Boston, United States with about 15 employees. Its market capitalization is roughly $28 million. In the fiscal year ended 2025-12-31, CRVO reported $0M in revenue and ($27M) in net income.
CervoMed Inc., a clinical-stage biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. The company is developing neflamapimod, an orally administered small molecule drug that crosses the bloodbrain barrier and inhibits the enzyme p38a.
Interactive charts & full statements → Open the CRVO valuation workbench →
| Income statement | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Revenue | $0M | $0M | $0M | $0M | — |
| Operating Income (EBIT) | ($28M) | ($18M) | ($8M) | ($4M) | — |
| Net Income | ($27M) | ($16M) | ($2M) | ($6M) | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly income statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
|---|---|---|---|---|---|---|
| Total Revenue | $0M | $0M | $0M | $0M | $0M | — |
| Operating Income (EBIT) | ($8M) | ($8M) | ($8M) | ($7M) | ($5M) | — |
| Net Income | ($8M) | ($8M) | ($8M) | ($6M) | ($5M) | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Assets | $23M | $43M | $10M | $4M | — |
| Total Liabilities | $5M | $4M | $3M | $37M | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive CRVO viewer.
About TickerBase · Data methodology & sources